CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Items 501–584 of 584
Delbono, O., Wang, Z., & Messi, M. L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102999 · Cited by 7
Liquid Chromatography Tandem Mass Spectrometry Analysis of Tau Phosphorylation
Mendoza, J., Dolios, G., & Wang, R. (2015) · Neuromethods · doi:10.1007/7657_2015_84 · Cited by 2
Mueller, K. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-45190-4_4 · Cited by 5
Wang, Y., Shan, J., Zhang, L., Wang, R., Wu, M.-Y., Li, H., & Xu, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117445 · Cited by 3
Biomarkers for Alzheimer’s Disease: Imagination or Reality-View and Review!
Yassin, M., Armaly, Z., Bisharat, B., & Bowirrat, A. (2013) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2013.35040 · Cited by 2
Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis
Elmoualij, B., Dupiereux-Fettweis, I., Seguin, J., Quadrio, I., Zorzi, W., Perret‐Liaudet, A., & Heine, E. (2011) · InTech eBooks · doi:10.5772/17003 · Cited by 2
Alzheimer’s Disease and Other Neurodegenerative Disorders
Rosén, C., Zetterberg, H., & Blennow, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_20 · Cited by 2
The Pattern of Cortical Lesions in Preclinical Stages
Braak, H., & Tredici, K. D. (2014) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-12679-1_7 · Cited by 3
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 4
Schaeffer, M. J., Initiative, A. D. N., & Callahan, B. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180962 · Cited by 2
19 MRI as a Surrogate Marker in Clinical Trials in Alzheimer’s Disease
Jessen, F., & Hampel, H. J. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0019 · Cited by 3
Self-citationNeuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases
Irwin, D. J. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029876 · Cited by 2
Stomrud, E. (2009) · Lund University Publications (Lund University) · Cited by 2
Usefulness of Cerebrospinal Fluid Biomarkers in Diagnosis of Early Alzheimer's Disease
Herukka, S. (2007) · Cited by 2
Hao, Q., Fu, Y., Zhao, Y., Zhang, Z., Li, Z., Zhang, M., Xiong, S., Wang, Y., Tan, L., & Tan, M. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70174 · Cited by 1
Hu, Q., Xu, K., Ran, Q., Zhang, W., Gan, C., Fang, Q., & Hui, A. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111848 · Cited by 2
Dybing, K. M., Gao, S., Saykin, A. J., Risacher, S. L., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401201 · Cited by 1
Sharma, S., Rawat, E., Sharma, P., & Kapoor, D. U. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00231-2 · Cited by 1
Mazahir, F., Rahi, V., Kumar, A., Kaundal, R. K., & Yadav, A. K. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102934 · Cited by 1
Dadsena, R., Costa, A. S., David, S., Haberl, L., Schulz, J. B., Reetz, K., & Haeger, A. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70233 · Cited by 3
Inhibition of Tau Phosphorylation as a Potential Strategy in Treatment of Parkinson’s Disease
Wenya, W. (2011) · InTech eBooks · doi:10.5772/20724 · Cited by 1
Diagnostic précoce de la maladie d’Alzheimer
Saint‐Aubert, L., Puel, M., Chollet, F., & Pariente, J. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.006 · Cited by 6
The Value of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Dementia
Bastard, N. L., & Engelborghs, S. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.11 · Cited by 1
Exploration clinique des troubles cognitifs chez les sujets âgés
Hugonot-Diener, L., Duron, E., Labouree, F., & Rigaud, A. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)70019-6 · Cited by 1
Piccini, A. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010025 · Cited by 1
Naskar, A., Jayanty, D., Head, K. Z., Khanna, G. L., Vatsalya, V., & Banerjee, A. (2023) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2023.134005 · Cited by 1
Neuroimaging Advances in Alzheimer's Disease
Schonhaut, D. R., & Rabinovici, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00017-2 · Cited by 4
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies
Dubois, B., Villain, N., Jacova, C., & Uspenskaya, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_13 · Cited by 1
Neurodegenerative and movement disorders
(2012) · CRC Press eBooks · doi:10.1201/b13258-14 · Cited by 1
CSF biomarkers in dementia: longitudinal aspects and combination with MRI
Bouwman, F. H. (2008) · Pure Amsterdam UMC · Cited by 4
Strategies for Alzheimer's Disease Diagnosis
Estrada, L. D., & Soto, C. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-87995-6_18 · Cited by 1
Alzheimer's disease-associated biomarkers in delirium and cognitively normal older adults
Idland, A. (2020) · NVA (Nasjonalt vitenarkiv) · Cited by 2
Biomarkers and Surrogate Markers in Drug Development
Cutler, N. R., Sramek, J. J., Murphy, M. F., Riordan, H., Bieck, P. R., & Carta, A. (2010) · Wiley eBooks · doi:10.1002/9781444318579.ch4
Dementia with Lewy bodies —an Investigation of Cause and Consequence
Boström, F. (2009) · Lund University Publications (Lund University)
Balasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Inhibition of Protein Amyloidosis by Glycomaterials
Miura, Y. (2009) · Trends in Glycoscience and Glycotechnology · doi:10.4052/tigg.21.324
Krolak‐Salmon, P., & Vighetto, A. (2012) · Future Neurology · doi:10.2217/fnl.12.39 · Cited by 1
SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Alzheimer subgroups: towards effective drug development
Iqbal, K., & Grundke, I. (2006) · Future Neurology · doi:10.2217/14796708.2.1.3
Impact of the IWG/Dubois Criteria for Alzheimer’s Disease in Imaging Studies
Dubois, B., & Uspenskaya, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_13
Génétique des formes autosomiques dominantes de maladie d’Alzheimer
Wallon, D., Campion, D., & Hannequin, D. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0443-9_9
Fluid biomarkers in Alzheimer's disease - current
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013)
Development of magnetic resonance imaging techniques for mouse models of Alzheimer's Disease
O’Callaghan, J. M. (2015) · UCL Discovery (University College London)
Current Understanding of Chronic Traumatic
Stern, R. A., & McKee, A. C. (2014)
Fluid Biomarkers and Diagnostics
Zetterberg, H., & Blennow, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00021-6
New Small Molecule Drug Discovery for Alzheimer's Disease
Liu, K., Zhang, M., & Nagappan, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-6
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5 · Cited by 1
Connectivity Based Characterization of Brain Function in Humans and Dogs
Zhao, S. (2017) · Cited by 1
Sjödin, S. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Charakterisierung von Prädiktoren rapid-progressiver Verläufe des M. Alzheimer
Bartlau, T. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5745
Hansson, K. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Calvo, M. A. (2017) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/29463
Tau proteolysis mechanisms and relevance for tauopathies
Quinn, J. P. (2019) · Research Explorer (The University of Manchester)
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., & Zetterberg, H. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_9
Recent advances in blood and gut microbiota biomarkers for Alzheimer’s disease
Wu, S., Li, H., Tong, L., & Zhou, L. I. U. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0100
Mathématiques pour les sciences de la vie
(2014) · Dunod eBooks · doi:10.3917/dunod.david.2014.01.0177
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804538-1.00036-5
Mistlberger, R. E., & Kent, B. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734840494.793555104
Fusion of Multimodality Features for Improved Classification of Alzheimer DiseasePreprint
Shobha, S., & Karthikeyan, B. R. (2022) · Research Square · doi:10.21203/rs.3.rs-1676817/v1
Inflamasi dalam Patologi Penyaki Alzheimer
Purba, J. S. (2020) · MEDICINUS · doi:10.56951/medicinus.v33i3.70 · Cited by 3
Imaging early brain characteristics of alzheimer’s disease: Structure, function and symptomatology
van Hooren, R. W. E. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221215rh
Exploratory Blood Biomarker Patterns in a Mixed Dementia CohortPreprint
Gezegen, H., Alaylıoğlu, M., Şahin, E., Swann, O., Veleva, E., Güven, G., Yaman, Ü., Salih, D. A. M., Bılgıç, B., Hanağası, H. A., et al. (2024) · medRxiv · doi:10.1101/2024.11.07.24316927 · Cited by 1
Tang, Z., Guo, M., Ding, Y., Wen, Y., Li, B., Xiao, Y., Ni, R., Guan, Z.-Z., & Qi, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.24.625068 · Cited by 1
New Research on Biomarkers in Alzheimer’s Continuum
Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615 · Cited by 3
Perkovic, M. N., Leko, M. B., Erjavec, G. N., Milos, T., Vuic, B., Borovečki, F., Šimić, G., & Pivac, N. (2025) · Brain Mechanisms · doi:10.1016/j.bramec.2025.202495 · Cited by 1
Hu, Q., Xu, K. L., Ran, Q., Zhang, W., Gan, C., Fang, Q., & Hui, A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5186865
Strużek, K., Karamus, K., Rejmak, R. W., Borowska-Łygan, M., Urban, W., Tomaszewski, J., Gryc, A., Lipiec, J., & Grudzień, M. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.60238 · Cited by 1
Hosseini, S. F., Akbarabadi, P., Noorani, F., Kazemi, D., Sadeghsalehi, H., Fattahpour, M., Sheybani‐Arani, M., Noroozi, M., Kazemi, A., & Initiative, A. D. N. (2025) · Current Alzheimer Research · doi:10.2174/0115672050379856250529113023
Prawiroharjo, P., Vidyanti, A. N., Syafrita, Y., Yunus, R. E., Fakhri, A., Martalia, V., Gabrielle, A., Rahmayani, S. A., Marcel, G., Wijaya, V. G., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16071050
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Andriuta, D. (2019) · theses.fr (ABES) · doi:10.70675/9bc67e49z5496z4d82z8bf5zff9f44d856c0
Signatures épigénétiques de la maladie d'Alzheimer dans l'ADN libre circulant
Guemri, J. (2021) · theses.fr (ABES) · doi:10.70675/aa3cb199zc068z4b72zab7fz6deb0fe1de87
Célestine, M. (2023) · theses.fr (ABES) · doi:10.70675/873ca377z9a97z43f6z8051zdab4082686ba · Cited by 1
Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
Matta, K. (2024) · theses.fr (ABES) · doi:10.70675/cea4fe5ez67c3z4445z92f7z39af62ba059b
Van, K. T. (2025) · theses.fr (ABES) · doi:10.70675/32a1a6cez5dd3z42c0za2eaz2e57807081a6
Early Prognosis of Alzheimer's Disease: Diagnostic Biomarker Review Article
Maghmomeh, A., Alkhoder, L., Turk, B., Habbal, A., & AL-Afandi, D. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00688
Vidyanti, A. N., Prawiroharjo, P., Syafrita, Y., Prodjohardjono, A., Rahmadini, A., Hidayatun, P. I. R., Rahman, R., Divina, E., Permata, R. I., Tazkia, A. A., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261497299
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.